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incidence
Gastrointestinal stromal tumours (GIST) are rare tumours,
with an estimated incidence of 1.5/100 000/year.
diagnosis
When GIST present as a small esophago-gastric or duodenal
nodule £2 cm in size, endoscopic biopsy may be difficult, and
laparoscopic/laparotomic excision may be the only way to get
to a histologic diagnosis. Many of these small nodules are low-
risk GIST or entities whose clinical significance remains unclear.
Therefore, the standard approach to these patients is
endoscopic ultrasound assessment and then follow-up,
reserving excision for patients whose tumour increases in size.
Alternatively, the decision can be shared with the patient to
make a histologic assessment. On the other hand, the standard
approach to nodules >2 cm in size is biopsy/excision, because,
if GIST, they imply a higher risk. The standard approach to
rectal (or recto-vaginal space) nodules is biopsy/excision after
ultrasound assessment regardless of the tumour size, because
the risk is higher and the local implications for surgery are
more critical. However, a follow-up policy may be an option,
shared with the patient in the case of small lesions. If there is an
abdominal nodule not amenable to endoscopic assessment,
laparoscopic/laparotomic excision is the standard approach. If
there is a bigger mass, especially if surgery is likely to be
a multivisceral resection, multiple core needle biopsies are the
standard approach. This may let the surgeon plan the best
approach according to the histologic diagnosis and may avoid
surgery for diseases which do not merit it (e.g. lymphomas,
mesenteric fibromatosis, germ cell tumours). The risk of
peritoneal contamination is negligible if the procedure is
properly carried out. Lesions at risk in this regard (e.g. cystic
masses) should be biopsied in specialized centres. Immediate
laparoscopic/laparotomic excision is an alternative on an
individualized basis, especially if surgery is limited. If a patient
presents with obvious metastatic disease, then a biopsy of the
metastatic focus is sufficient and the patient usually does not
require a laparotomy for diagnostic purposes. The tumour
sample should be fixed in formalin (Bouin fixation should be
avoided, since it may impair the feasibility of molecular
analysis). Frozen tissue collection is encouraged, because new
molecular pathology assessments may become available later on
and be made in the patient’s interest. Appropriate informed
consent should be sought to allow for later analysis and further
research as long as this is allowed by local and national
guidelines.
Pathologically, the diagnosis of GIST relies on morphology
and immunohistochemistry. CD117 is generally positive,
although a proportion of true GIST (in the 5% range) is
CD117-negative. Antigen retrieval may result in false positive
CD117 staining. Mitotic count has prognostic value, and
should be expressed as number of mitoses per 50 HPF.
Mutational analysis for known mutations involving KIT and
PDGFRA genes can confirm the diagnosis of GIST, if doubtful
(particularly in CD117-negative suspect GIST). In addition,
mutational analysis has predictive value for sensitivity to
imatinib and prognostic value, so that it is strongly
recommended in the diagnostic work-up of all GIST.
Centralization of mutational analysis in a laboratory enrolled in
an external quality assurance program and with expertise in the
disease may be useful in order to make mutational analysis
more widely available.
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staging and risk assessment
The risk of relapse may be estimated on the basis of some
prognostic factors, which should be recorded on a standard
basis: mitotic rate, tumour size, tumour site, surgical margins
(including whether tumour rupture occurred). Tumour size
and mitotic count are considered by the 2002 Consensus risk
classification. This was correlated with prognosis in an
epidemiological study, showing that the ‘high risk’ category has
a much worse prognosis than the others. ‘Very low risk’ and
‘low risk’ categories have a very favourable prognosis. In most
of the population-based series, the ‘intermediate risk’ category
of the Consensus classification did not discriminate patients
with an unfavourable prognosis.
A more recently proposed risk partitioning incorporates
tumour site in addition to the mitotic count and primary
tumour size. In particular, it reflects the fact that gastric GIST
have a better prognosis than small bowel or rectal GIST. The
risk estimate for subgroups is based on a single retrospective
analysis, and therefore needs confirmation. However, this
classification better distinguishes across different risk levels.
Tumour rupture, whether spontaneous or at the time of
surgical resection, should be recorded, because it denotes
a highly adverse prognostic value due to peritoneal
contamination. However, it is uncertain whether these patients
should be considered metastatic. Abdominal washing during
surgery may be an option in case of tumour rupture. Careful
surgical exploration for small peritoneal nodules is important.
Staging procedures take into account the fact that most
relapses affect the peritoneum and the liver. Contrast-enhanced
abdominal and pelvic CT scan is of choice for staging and
follow-up. MRI may be an alternative. For rectal GIST, MRI
provides better preoperative staging information. Chest CT
scan or X-rays and routine laboratory testing complement the
staging work-up of the asymptomatic patient. Evaluation of
FDG uptake using PET scan, or PET–CT/MRI, is useful mainly
when early detection of tumour response to imatinib treatment
is of special concern.
treatment
Multidisciplinary treatment planning is needed (involving
pathologists, radiologists, surgeons and medical oncologists),
such as that which is available in reference centres for sarcomas
and GIST, and/or within reference networks sharing
multidisciplinary expertise.
limited disease
Standard treatment of localized GIST is complete surgical
excision, without dissection of clinically negative lymph nodes
[IV, A]. If laparoscopic excision is planned, the technique needs
to follow the principles of oncologic surgery. A laparoscopic
approach is clearly discouraged in patients who have large
tumours. R0 excision is the goal. If an R1 excision has been
made, re-excision may be a choice, provided the original site of
lesion can be found and major functional sequelae are not
foreseen. When R0 surgery implies major functional sequelae,
and preoperative medical treatment has not helped or cannot
be foreseen, the decision can be shared with the patient to
accept R1 margins, particularly for low-risk lesions, in the lack
of a formal demonstration that R1 surgery is associated with
a worse overall survival. Patient referral to a specialized centre
should be considered, and R0 resection should be considered as
the reference standard. If R0 surgery is not feasible, or it might
be achieved through less mutilating surgery in the case of
cytoreduction, imatinib pretreatment is recommended [IV, A].
This may also be the case if the surgeon believes that the
surgical conduct is safer after cytoreduction (e.g. the risk of
bleeding and tumour rupture is decreased). Following maximal
tumour response, generally after 6–12 months, surgery is
performed. Mutational analysis may help to exclude non-
sensitive mutations from therapy with imatinib. PET scan, or
PET CT/MRI, may be particularly useful to assess tumour
response very rapidly, in terms of a few weeks, so that surgery is
not delayed in the case of non-responding disease.
The risk of relapse can be substantial in many presentations,
depending on mitotic count, tumour size and site of disease.
Given the efficacy of imatinib in the disease, adjuvant treatment
with the drug has been studied. Overall survival data are still
not available from any of the conducted studies, but one
randomized, placebo-controlled trial demonstrated that
imatinib dosed for 1 year in planned duration is able to prolong
early relapse-free survival in completely resected >3 cm
localized GIST. A longer follow-up is needed to draw definitive
conclusions with regard to the absolute relapse rate after
a substantial time interval, the length of the delay in relapse and
the time to secondary resistance to imatinib in subsequently
relapsing patients. Currently, there is no open trial of adjuvant
imatinib. At the moment, there is no global consensus in the
medical community on adjuvant imatinib as standard
treatment for GIST patients with localized disease. Having been
approved by regulatory bodies as EMEA and FDA, adjuvant
imatinib can be proposed as an option for those patients with
a substantial risk of relapse, for shared decision-making in
conditions of uncertainty [II, C]. In addition to the risk
assessment, mutational analysis may guide the selection of
those patients who are more likely to benefit from the
treatment. If the decision is made to use imatinib as an
adjuvant, the currently available trial data support its use for
one year. The results are awaited of a trial which compared one
versus three years of treatment duration.
extensive disease
In locally advanced inoperable patients and metastatic patients,
imatinib is standard treatment [IV, A]. This applies also to
metastatic patients who have been completely relieved of all
lesions surgically, being discovered unexpectedly. Standard
dose of imatinib is 400 mg daily [I, A]. Data have been
provided that patients with exon 9 KIT mutations fare better in
terms of progression-free survival on a higher dose level, i.e.
800 mg daily, which is therefore standard treatment in this
subgroup [III, A]. Treatment should be continued indefinitely,
since treatment interruption is generally followed by relatively
rapid tumour progression in virtually all cases, even when
lesions have been previously surgically excised [II, B]. Dose
intensity should be maintained by proper management of side
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effects and a correct policy of dose reductions and interruptions
in the case of excessive, persistent toxicity. Close monitoring of
tumour response should be continued throughout treatment,
since the risk of secondary progression persists over time.
Complete excision of residual metastatic disease has been
shown to be related to a good prognosis, provided the patient is
responding to imatinib, but it is left to be demonstrated
whether this is due to surgery or to a selection bias. Therefore,
surgery of metastatic responding patients is considered
investigational.
The standard approach in the case of tumour progression is
to increase the imatinib dose to 800 mg daily [III, B]. This may
be useful in case of a KIT exon 9 mutated GIST, if the patient
started at 400 mg; probably in case of changes in drug
pharmacokinetics over time (which is amenable to assessment
and constitutes a subject of study), or, possibly, in case of some
secondary molecular alterations. Also patient non-compliance
should be ruled out as a possible cause of tumour progression,
as well as drug interactions with concomitant medications. In
case of progression or intolerance on imatinib, second-line
standard treatment is sunitinib [II, B]. The drug was proved
effective in terms of progression-free survival following a ‘4
weeks on–2 weeks off’ regimen. Data have been provided that
a continuously dosed daily oral regimen with a lower daily dose
may be effective and well tolerated, although no formal
comparison has been performed within a randomized clinical
trial. This schedule can therefore be considered an option on an
individualized basis.
After failing on sunitinib, the patient with metastatic GIST
should be considered for participation in a clinical trial of new
therapies or new combinations. Surgical excision of progressing
disease has not been rewarding in published series, but surgery
of limited progression, such as the ‘nodule within a mass’, has
been associated with a progression-free interval in the same
range as for second-line treatment with sunitinib. Therefore, it
may be a palliative option in the individual patient with
a limited progression. Non-surgical procedures (local
treatment, such as ablations, etc.) may be selected. There is
anecdotal evidence that patients who have already progressed
on imatinib may occasionally have a benefit when rechallenged
with the same drug. Likewise, maintaining treatment with an
anti-tyrosine kinase agent even in the case of progressive disease
may slow down progression as opposed to stopping it, of
course if no other option is available at the time. Therefore,
rechallenge or continuation treatment with an antityrosine
kinase agent to which the patient has already been exposed may
be an option in individual cases. On the other hand,
combinations of anti-tyrosine kinase agents should be
discouraged outside of clinical studies, because of the potential
for considerable toxicity.
response evaluation
Antitumour activity translates into tumour shrinkage in the
majority of patients, but some patients may show only changes
in tumour density on CT scan, or these changes may precede
a delayed tumour shrinkage. These changes in tumour
radiological appearance should be considered as tumour
response. In particular, even some increase in tumour size may
be indicative of tumour response if tumour density on CT scan
is decreased. Even the ‘appearance’ of new lesions may depend
on their being more evident when becoming less dense.
Therefore, both tumour size and tumour density on CT scan,
or consistent changes on MRI, should be considered as criteria
for tumour response. FDG–PET scan has proved to be highly
sensitive in early assessment of tumour response, and may be
useful in doubtful cases, or when early prediction of response is
highly useful (e.g. preoperative cytoreductive treatments). The
absence of tumour progression after months of treatment
equally amounts to tumour response. On the other hand,
tumour progression may not be accompanied by changes
in tumour size. In fact, some increase in tumour density
within tumour lesions may be indicative of tumour
progression. A typical progression pattern is the ‘nodule within
the nodule’, by which a portion of a responding lesion becomes
hyperdense.
follow-up
There are no published data supporting specific policies for
follow-up of surgically treated patients with localized disease.
Relapses most often occur to the peritoneum or in the liver.
The mitotic rate likely affects the speed at which relapses take
place. Risk assessment based on mitotic count, tumour size and
tumour site may help in choosing the routine follow-up policy.
High-risk patients generally relapse within 2–3 years, while low-
risk patients may relapse later, although much less likely. That
said, routine follow-up schedules differ across institutions. As
an example, in some institutions intermediate–high-risk
patients undergo a routine follow-up with CT scan every 3–4
months for 3 years, then every 6 months until 5 years, and
yearly afterwards; for low-risk tumours, follow-up is carried out
with CT scan every 6 months for 5 years. Very low risk GIST
probably do not deserve routine follow-up, although one must
be aware that the risk is not nil.
note
These Clinical Recommendations update those formulated in
2008 following a consensus process based on a consensus event
organized by ESMO in Lugano in October 2007. The consensus
update in early 2009 and the previous event involved the same
experts from the community of the European sarcoma research
groups and from some sarcoma reference centres outside
Europe. Their names are indicated hereafter. The text reflects
an overall consensus among them, although each of them may
not necessarily find it consistent with his/her own views. The
EU-funded network of excellence CONTICANET (CONnective
TIssue CAncers NETwork) supported the consensus process.
consensus panel:
Paolo G. Casali, Milano, Italy (Coordinating author)
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Levels of evidence [I–V] and grades of recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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